Key features and details
- Expression system: Saccharomyces cerevisiae
- Purity: > 90% SDS-PAGE
- Endotoxin level: < 1.000 Eu/µg
- Active: Yes
- Suitable for: HPLC, SDS-PAGE, Functional Studies
Product nameRecombinant human Osteoprotegerin protein (Fc Chimera Active)
See all Osteoprotegerin proteins and peptides
Determined by its ability to neutralize the stimulation of U937 cells treated with 10 ng/ml of soluble RANKL.
Purity> 90 % SDS-PAGE.
Endotoxin level< 1.000 Eu/µg
Expression systemSaccharomyces cerevisiae
Protein lengthProtein fragment
Predicted molecular weight47 kDa
Amino acids22 to 201
Additional sequence informationRecombinant ab200259 contains 412 amino acid residues, including 180 residues from mature Osteoprotegerin (aa 22-201) and 232 residues from the Fc protein of Human IgG1.
Our Abpromise guarantee covers the use of ab200259 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This lyophilized preparation is stable at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Please see notes section. Store under desiccating conditions.
Constituent: 100% PBS
Lyophilized from a 0.2 um filtered concentrated solution.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ReconstitutionReconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL.
FunctionActs as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Tissue specificityHighly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in diseaseDefects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
Sequence similaritiesContains 2 death domains.
Contains 4 TNFR-Cys repeats.
modificationsN-glycosylated. Contains sialic acid residues.
The N-terminus is blocked.
- Information by UniProt
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab200259 has not yet been referenced specifically in any publications.